Skip to main content
Top
Published in: Applied Health Economics and Health Policy 3/2016

Open Access 01-06-2016 | Current Opinion

Methodological Challenges to Economic Evaluations of Vaccines: Is a Common Approach Still Possible?

Authors: Mark Jit, Raymond Hutubessy

Published in: Applied Health Economics and Health Policy | Issue 3/2016

Login to get access

Abstract

Economic evaluation of vaccination is a key tool to inform effective spending on vaccines. However, many evaluations have been criticised for failing to capture features of vaccines which are relevant to decision makers. These include broader societal benefits (such as improved educational achievement, economic growth and political stability), reduced health disparities, medical innovation, reduced hospital beds pressures, greater peace of mind and synergies in economic benefits with non-vaccine interventions. Also, the fiscal implications of vaccination programmes are not always made explicit. Alternative methodological frameworks have been proposed to better capture these benefits. However, any broadening of the methodology for economic evaluation must also involve evaluations of non-vaccine interventions, and hence may not always benefit vaccines given a fixed health-care budget. The scope of an economic evaluation must consider the budget from which vaccines are funded, and the decision-maker’s stated aims for that spending to achieve.
Literature
1.
go back to reference Whitney C, Zhou F, Singleton J, Schuchat A. Benefits from immunization during the vaccines for children program era—United States, 1994–2013. MMWR Morb Mortal Wkly RepWR. 2014;63:352–5. Whitney C, Zhou F, Singleton J, Schuchat A. Benefits from immunization during the vaccines for children program era—United States, 1994–2013. MMWR Morb Mortal Wkly RepWR. 2014;63:352–5.
5.
go back to reference Kim S-Y, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics. 2008;26:191–215.CrossRefPubMed Kim S-Y, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics. 2008;26:191–215.CrossRefPubMed
6.
go back to reference Gessner BD, Duclos P, Deroeck D, Nelson EAS. Informing decision makers: experience and process of 15 National Immunization Technical Advisory Groups. Vaccine. 2010;28(Suppl 1):A1–5.CrossRefPubMed Gessner BD, Duclos P, Deroeck D, Nelson EAS. Informing decision makers: experience and process of 15 National Immunization Technical Advisory Groups. Vaccine. 2010;28(Suppl 1):A1–5.CrossRefPubMed
7.
go back to reference Klein E. Wonkblog. Bill Gates: ‘Death is something we really understand extremely well’. Washington Post. 2013 May 17; Klein E. Wonkblog. Bill Gates: ‘Death is something we really understand extremely well’. Washington Post. 2013 May 17;
9.
go back to reference Beutels P, Jit M. A brief history of economic evaluation for human papillomavirus vaccination policy. Sex Heal. 2010;7:352–8.CrossRef Beutels P, Jit M. A brief history of economic evaluation for human papillomavirus vaccination policy. Sex Heal. 2010;7:352–8.CrossRef
10.
go back to reference Christensen H, Trotter CL, Hickman M, Edmunds WJ. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ. 2014;349:g5725.CrossRefPubMedPubMedCentral Christensen H, Trotter CL, Hickman M, Edmunds WJ. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ. 2014;349:g5725.CrossRefPubMedPubMedCentral
11.
go back to reference Yothasamut J, Putchong C, Sirisamutr T, Teerawattananon Y, Tantivess S. Scaling up cervical cancer screening in the midst of human papillomavirus vaccination advocacy in Thailand. BMC Health Serv. Res. 2010;10(Suppl 1):S5.CrossRefPubMedPubMedCentral Yothasamut J, Putchong C, Sirisamutr T, Teerawattananon Y, Tantivess S. Scaling up cervical cancer screening in the midst of human papillomavirus vaccination advocacy in Thailand. BMC Health Serv. Res. 2010;10(Suppl 1):S5.CrossRefPubMedPubMedCentral
12.
go back to reference Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, et al. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organisation; 2003. Geneva: World Health Organisation; 2003. Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, et al. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organisation; 2003. Geneva: World Health Organisation; 2003.
13.
go back to reference Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1253–8.CrossRefPubMed Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1253–8.CrossRefPubMed
16.
go back to reference Laxminarayan R, Jamison DT, Krupnick AJ, Norheim OF. Valuing vaccines using value of statistical life measures. Vaccine. 2014;32:5065–70.CrossRefPubMed Laxminarayan R, Jamison DT, Krupnick AJ, Norheim OF. Valuing vaccines using value of statistical life measures. Vaccine. 2014;32:5065–70.CrossRefPubMed
17.
go back to reference Ozawa S, Stack ML, Bishai DM, Mirelman A, Friberg IK, Niessen L, et al. During the ‘decade of vaccines,’ the lives of 6.4 million children valued at $231 billion could be saved. Health Aff. (Millwood). 2011;30:1010–20. Ozawa S, Stack ML, Bishai DM, Mirelman A, Friberg IK, Niessen L, et al. During the ‘decade of vaccines,’ the lives of 6.4 million children valued at $231 billion could be saved. Health Aff. (Millwood). 2011;30:1010–20.
18.
go back to reference Carroll S, Rojas AJG, Glenngård AH, Marin C. Vaccination: short- to long-term benefits from investment. J Mark Access Heal Policy. 2015;3:27279. Carroll S, Rojas AJG, Glenngård AH, Marin C. Vaccination: short- to long-term benefits from investment. J Mark Access Heal Policy. 2015;3:27279.
19.
go back to reference Demarteau N, Breuer T, Standaert B. Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program. Pharmacoeconomics. 2012;30:337–53.CrossRefPubMed Demarteau N, Breuer T, Standaert B. Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program. Pharmacoeconomics. 2012;30:337–53.CrossRefPubMed
20.
21.
go back to reference Verguet S, Murphy S, Anderson B, Johansson KA, Glass R, Rheingans R. Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis. Vaccine. 2013;31:4902–10.CrossRefPubMed Verguet S, Murphy S, Anderson B, Johansson KA, Glass R, Rheingans R. Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis. Vaccine. 2013;31:4902–10.CrossRefPubMed
22.
go back to reference Etienne C, Asamoa-Baah A, Evans D. Health systems financing: the path to universal coverage. Geneva: World Health Organization; 2010. Etienne C, Asamoa-Baah A, Evans D. Health systems financing: the path to universal coverage. Geneva: World Health Organization; 2010.
23.
go back to reference Jit M, Brisson M. Modelling the epidemiology of infectious diseases for decision analysis: a primer. Pharmacoeconomics. 2011;29:371–86.CrossRefPubMed Jit M, Brisson M. Modelling the epidemiology of infectious diseases for decision analysis: a primer. Pharmacoeconomics. 2011;29:371–86.CrossRefPubMed
24.
go back to reference Beutels P, Scuffham PA, MacIntyre CR. Funding of drugs: do vaccines warrant a different approach? Lancet Infect Dis. 2008;8:727–33.CrossRefPubMed Beutels P, Scuffham PA, MacIntyre CR. Funding of drugs: do vaccines warrant a different approach? Lancet Infect Dis. 2008;8:727–33.CrossRefPubMed
25.
go back to reference Bärnighausen T, Bloom DE, Cafiero ET, O’Brien JC. Economic evaluation of vaccination: capturing the full benefits, with an application to human papillomavirus. Clin Microbiol Infect. 2012;18(Suppl 5):70–6.CrossRefPubMed Bärnighausen T, Bloom DE, Cafiero ET, O’Brien JC. Economic evaluation of vaccination: capturing the full benefits, with an application to human papillomavirus. Clin Microbiol Infect. 2012;18(Suppl 5):70–6.CrossRefPubMed
26.
go back to reference Miners A, Cairns J, Wailoo A. Department of Health proposals for including wider societal benefits into value based pricing: a description and critique. Sheffield: NICE Decision Support Unit, ScHARR, University of Sheffield; 2013. Miners A, Cairns J, Wailoo A. Department of Health proposals for including wider societal benefits into value based pricing: a description and critique. Sheffield: NICE Decision Support Unit, ScHARR, University of Sheffield; 2013.
27.
go back to reference Bärnighausen T, Berkley S, Bhutta ZA, Bishai DM, Black MM, Bloom DE, et al. Reassessing the value of vaccines. Lancet Glob Heal. 2014;2:e251–2.CrossRef Bärnighausen T, Berkley S, Bhutta ZA, Bishai DM, Black MM, Bloom DE, et al. Reassessing the value of vaccines. Lancet Glob Heal. 2014;2:e251–2.CrossRef
28.
go back to reference Sarfatti A, Martinón-Torres F, Nadel S. Vaccine evaluation: lessons from a meningococcal B vaccine. Arch Dis Child. 2015;100:514–6.CrossRefPubMed Sarfatti A, Martinón-Torres F, Nadel S. Vaccine evaluation: lessons from a meningococcal B vaccine. Arch Dis Child. 2015;100:514–6.CrossRefPubMed
29.
go back to reference Jit M, Hutubessy R, Png ME, Sundaram N, Audimulam J, Salim S, et al. The broader economic impact of vaccination: reviewing and appraising the strength of evidence. BMC Med. 2015;13:209.CrossRefPubMedPubMedCentral Jit M, Hutubessy R, Png ME, Sundaram N, Audimulam J, Salim S, et al. The broader economic impact of vaccination: reviewing and appraising the strength of evidence. BMC Med. 2015;13:209.CrossRefPubMedPubMedCentral
30.
go back to reference Jit M, Bilcke J, Mangen MJ, Salo H, Melliez H, Edmunds WJ, et al. Response to comment on article by Jit et al. ‘The cost effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe’. Vaccine. 2011;29:3732–3.CrossRef Jit M, Bilcke J, Mangen MJ, Salo H, Melliez H, Edmunds WJ, et al. Response to comment on article by Jit et al. ‘The cost effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe’. Vaccine. 2011;29:3732–3.CrossRef
31.
go back to reference Jit M, Mibei W. Discounting in the evaluation of the cost-effectiveness of a vaccination programme: A critical review. Vaccine. 2015;33:3788–94.CrossRefPubMed Jit M, Mibei W. Discounting in the evaluation of the cost-effectiveness of a vaccination programme: A critical review. Vaccine. 2015;33:3788–94.CrossRefPubMed
32.
go back to reference Beutels P, Van Doorslaer E, Van Damme P, Hall J. Methodological issues and new developments in the economic evaluation of vaccines. Expert Rev Vaccines. 2003;2:649–60.CrossRefPubMed Beutels P, Van Doorslaer E, Van Damme P, Hall J. Methodological issues and new developments in the economic evaluation of vaccines. Expert Rev Vaccines. 2003;2:649–60.CrossRefPubMed
33.
go back to reference Brown DS, Johnson FR, Poulos C, Messonnier ML. Mothers’ preferences and willingness to pay for vaccinating daughters against human papillomavirus. Vaccine. 2010;28:1702–8.CrossRefPubMed Brown DS, Johnson FR, Poulos C, Messonnier ML. Mothers’ preferences and willingness to pay for vaccinating daughters against human papillomavirus. Vaccine. 2010;28:1702–8.CrossRefPubMed
34.
go back to reference Coupé VMH, Bogaards JA, Meijer CJLM, Berkhof J. Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening. Vaccine. 2012;30:1813–22.CrossRefPubMed Coupé VMH, Bogaards JA, Meijer CJLM, Berkhof J. Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening. Vaccine. 2012;30:1813–22.CrossRefPubMed
35.
go back to reference Artzy-Randrup Y, Dobson AP, Pascual M. Synergistic and antagonistic interactions between bednets and vaccines in the control of malaria. Proc Natl Acad Sci USA. 2015;112:3014–9.CrossRefPubMedPubMedCentral Artzy-Randrup Y, Dobson AP, Pascual M. Synergistic and antagonistic interactions between bednets and vaccines in the control of malaria. Proc Natl Acad Sci USA. 2015;112:3014–9.CrossRefPubMedPubMedCentral
36.
go back to reference Brenzel L, Wolfson LJ, Fox-rushby J, Miller M, Halsey NA. Vaccine-Preventable Diseases. In: Disease Control Priorities in Developing Countries. 2nd Edn. Washington, D.C.: World Bank; 2006. p. 389–412. Brenzel L, Wolfson LJ, Fox-rushby J, Miller M, Halsey NA. Vaccine-Preventable Diseases. In: Disease Control Priorities in Developing Countries. 2nd Edn. Washington, D.C.: World Bank; 2006. p. 389–412.
37.
go back to reference Kim SY, Sweet S, Slichter D, Goldie SJ. Health and economic impact of rotavirus vaccination in GAVI-eligible countries. BMC Public Heal. 2010;10:253. Kim SY, Sweet S, Slichter D, Goldie SJ. Health and economic impact of rotavirus vaccination in GAVI-eligible countries. BMC Public Heal. 2010;10:253.
38.
go back to reference Sinha A, Levine O, Knoll MD, Muhib F, Lieu TA. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet. 2007;369:389–96.CrossRefPubMed Sinha A, Levine O, Knoll MD, Muhib F, Lieu TA. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet. 2007;369:389–96.CrossRefPubMed
39.
go back to reference Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Heal. 2014;2:e406–14.CrossRef Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Glob Heal. 2014;2:e406–14.CrossRef
41.
go back to reference Ben Hadj Yahia M-B, Jouin-Bortolotti A, Dervaux B. Extending the human papillomavirus vaccination programme to include males in high-income countries: a systematic review of the cost-effectiveness studies. Clin Drug Investig. 2015;35:471–85. Ben Hadj Yahia M-B, Jouin-Bortolotti A, Dervaux B. Extending the human papillomavirus vaccination programme to include males in high-income countries: a systematic review of the cost-effectiveness studies. Clin Drug Investig. 2015;35:471–85.
42.
go back to reference Lugnér AK, van der Maas N, van Boven M, Mooi FR, de Melker HE. Cost-effectiveness of targeted vaccination to protect new-borns against pertussis: comparing neonatal, maternal, and cocooning vaccination strategies. Vaccine. 2013;31:5392–7.CrossRefPubMed Lugnér AK, van der Maas N, van Boven M, Mooi FR, de Melker HE. Cost-effectiveness of targeted vaccination to protect new-borns against pertussis: comparing neonatal, maternal, and cocooning vaccination strategies. Vaccine. 2013;31:5392–7.CrossRefPubMed
43.
go back to reference Rozenbaum MH, van Hoek AJ, Vegter S, Postma MJ. Cost-effectiveness of varicella vaccination programs: an update of the literature. Expert Rev Vaccines. 2008;7:753–82.CrossRefPubMed Rozenbaum MH, van Hoek AJ, Vegter S, Postma MJ. Cost-effectiveness of varicella vaccination programs: an update of the literature. Expert Rev Vaccines. 2008;7:753–82.CrossRefPubMed
44.
go back to reference Choi YH, Jit M, Gay N, Andrews N, Waight P a., Melegaro A, et al. 7-valent pneumococcal conjugate vaccination in england and wales: Is it still beneficial despite high levels of serotype replacement? PLoS One. 2011;6:e26190. Choi YH, Jit M, Gay N, Andrews N, Waight P a., Melegaro A, et al. 7-valent pneumococcal conjugate vaccination in england and wales: Is it still beneficial despite high levels of serotype replacement? PLoS One. 2011;6:e26190.
45.
go back to reference Bin-Chia Wu D, Chaiyakunapruk N, Chong H-Y, Beutels P. Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: a review of economic evaluations (2006–2014). Vaccine. 2015;33:1633–58. Bin-Chia Wu D, Chaiyakunapruk N, Chong H-Y, Beutels P. Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: a review of economic evaluations (2006–2014). Vaccine. 2015;33:1633–58.
46.
go back to reference Brisson M, Van de Velde N, Boily M-C. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics. 2009;12:343–51.CrossRefPubMed Brisson M, Van de Velde N, Boily M-C. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics. 2009;12:343–51.CrossRefPubMed
47.
go back to reference Sugden R, Williams A. The principles of practical cost-benefit analysis. Oxford: Oxford University Press; 1978. Sugden R, Williams A. The principles of practical cost-benefit analysis. Oxford: Oxford University Press; 1978.
48.
go back to reference Jit M, Chapman R, Hughes O, Choi YH. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ. 2011;343:d5775.CrossRefPubMedPubMedCentral Jit M, Chapman R, Hughes O, Choi YH. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ. 2011;343:d5775.CrossRefPubMedPubMedCentral
49.
go back to reference Newall AT, Reyes JF, Wood JG, McIntyre P, Menzies R, Beutels P. Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses. Vaccine. 2014;32:759–65.CrossRefPubMed Newall AT, Reyes JF, Wood JG, McIntyre P, Menzies R, Beutels P. Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses. Vaccine. 2014;32:759–65.CrossRefPubMed
52.
go back to reference Jamison DT, Summers LH, Alleyne G, Arrow KJ, Berkley S, Binagwaho A, et al. Global health 2035: a world converging within a generation. Lancet. 2013;382:1898–955 (Elsevier). Jamison DT, Summers LH, Alleyne G, Arrow KJ, Berkley S, Binagwaho A, et al. Global health 2035: a world converging within a generation. Lancet. 2013;382:1898–955 (Elsevier).
53.
go back to reference Mina MJ, Metcalf CJE, de Swart RL, Osterhaus ADME, Grenfell BT. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science. 2015;348:694–9.CrossRefPubMedPubMedCentral Mina MJ, Metcalf CJE, de Swart RL, Osterhaus ADME, Grenfell BT. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science. 2015;348:694–9.CrossRefPubMedPubMedCentral
54.
go back to reference Anekwe TD, Newell M-L, Tanser F, Pillay D, Bärnighausen T. The causal effect of childhood measles vaccination on educational attainment: A mother fixed-effects study in rural South Africa. Vaccine. 2015;33:5020–6.CrossRefPubMedPubMedCentral Anekwe TD, Newell M-L, Tanser F, Pillay D, Bärnighausen T. The causal effect of childhood measles vaccination on educational attainment: A mother fixed-effects study in rural South Africa. Vaccine. 2015;33:5020–6.CrossRefPubMedPubMedCentral
55.
go back to reference Griffiths UK, Miners A. Economic evaluations of Haemophilus influenzae type b vaccine: systematic review of the literature. Expert Rev Pharmacoecon Outcomes Res. 2009;9:333–46.CrossRefPubMed Griffiths UK, Miners A. Economic evaluations of Haemophilus influenzae type b vaccine: systematic review of the literature. Expert Rev Pharmacoecon Outcomes Res. 2009;9:333–46.CrossRefPubMed
56.
go back to reference Bärnighausen T, Bloom D, Canning D. Rethinking the benefits and costs of childhood vaccination: The example of the Haemophilus influenzae type b vaccine. Vaccine. 2011;29:2371–80.CrossRefPubMed Bärnighausen T, Bloom D, Canning D. Rethinking the benefits and costs of childhood vaccination: The example of the Haemophilus influenzae type b vaccine. Vaccine. 2011;29:2371–80.CrossRefPubMed
57.
go back to reference Fesenfeld M, Hutubessy R, Jit M. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review. Vaccine. 2013;31:3786–804.CrossRefPubMed Fesenfeld M, Hutubessy R, Jit M. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review. Vaccine. 2013;31:3786–804.CrossRefPubMed
58.
go back to reference Beutels P, Thiry N, Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination—a review (2002–2006). Vaccine. 2007;25:1355–67.CrossRefPubMed Beutels P, Thiry N, Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination—a review (2002–2006). Vaccine. 2007;25:1355–67.CrossRefPubMed
59.
go back to reference van de Vooren K, Duranti S, Curto A, Garattini L. Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies. Pharmacoeconomics. 2014;32(1):29–45.CrossRefPubMed van de Vooren K, Duranti S, Curto A, Garattini L. Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies. Pharmacoeconomics. 2014;32(1):29–45.CrossRefPubMed
60.
go back to reference Aballéa S, Millier A, Quilici S, Caroll S, Petrou S, Toumi M. A critical literature review of health economic evaluations of rotavirus vaccination. Hum Vaccin Immunother. 2013;9:1272–88.CrossRefPubMedPubMedCentral Aballéa S, Millier A, Quilici S, Caroll S, Petrou S, Toumi M. A critical literature review of health economic evaluations of rotavirus vaccination. Hum Vaccin Immunother. 2013;9:1272–88.CrossRefPubMedPubMedCentral
61.
go back to reference Bilcke J, Van Damme P, Beutels P. Cost-effectiveness of rotavirus vaccination: Exploring caregiver(s) and ‘No Medical Care’ Disease Impact in Belgium. Med Decis Making. 2008;29:33–50.CrossRefPubMed Bilcke J, Van Damme P, Beutels P. Cost-effectiveness of rotavirus vaccination: Exploring caregiver(s) and ‘No Medical Care’ Disease Impact in Belgium. Med Decis Making. 2008;29:33–50.CrossRefPubMed
62.
go back to reference Loganathan T, Lee W-S, Lee K-F, Jit M, Ng C-W. Household catastrophic healthcare expenditure and impoverishment due to rotavirus gastroenteritis requiring hospitalization in Malaysia. PLoS One. 2015;10:e0125878.CrossRefPubMedPubMedCentral Loganathan T, Lee W-S, Lee K-F, Jit M, Ng C-W. Household catastrophic healthcare expenditure and impoverishment due to rotavirus gastroenteritis requiring hospitalization in Malaysia. PLoS One. 2015;10:e0125878.CrossRefPubMedPubMedCentral
Metadata
Title
Methodological Challenges to Economic Evaluations of Vaccines: Is a Common Approach Still Possible?
Authors
Mark Jit
Raymond Hutubessy
Publication date
01-06-2016
Publisher
Springer International Publishing
Published in
Applied Health Economics and Health Policy / Issue 3/2016
Print ISSN: 1175-5652
Electronic ISSN: 1179-1896
DOI
https://doi.org/10.1007/s40258-016-0224-7

Other articles of this Issue 3/2016

Applied Health Economics and Health Policy 3/2016 Go to the issue